• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Application of (1R,4S)-2-Azabicyclo[2.2.1]heptane (CAS: 380228-01-3) in Chemical Biology and Pharmaceutical Research

The compound (1R,4S)-2-azabicyclo[2.2.1]heptane (CAS: 380228-01-3) has garnered significant attention in recent years due to its unique structural properties and potential applications in drug discovery and chemical biology. This bicyclic scaffold serves as a versatile building block for the synthesis of novel pharmacophores, particularly in the development of central nervous system (CNS) therapeutics and enzyme inhibitors. Recent studies have demonstrated its efficacy in modulating various biological targets, including neurotransmitter receptors and metabolic enzymes.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of (1R,4S)-2-azabicyclo[2.2.1]heptane derivatives as selective norepinephrine reuptake inhibitors (NRIs). The researchers employed a structure-activity relationship (SAR) approach to optimize the compound's binding affinity, resulting in a lead candidate with improved pharmacokinetic properties and reduced off-target effects. The study highlighted the scaffold's ability to maintain rigid conformation while allowing for strategic modifications at the nitrogen and carbon positions.

In the field of enzyme inhibition, a recent breakthrough was reported in ACS Chemical Biology, where (1R,4S)-2-azabicyclo[2.2.1]heptane-based compounds were designed as potent inhibitors of histone deacetylases (HDACs). The constrained bicyclic structure was found to enhance selectivity for HDAC6 isoform, offering new possibilities for cancer therapy with reduced side effects. Molecular docking studies revealed that the scaffold's three-dimensional geometry perfectly complements the enzyme's active site topology.

From a synthetic chemistry perspective, innovative methodologies have been developed for the efficient production of (1R,4S)-2-azabicyclo[2.2.1]heptane derivatives. A 2024 publication in Organic Letters described a novel asymmetric catalytic route that significantly improves the enantiomeric purity of the compound while reducing the number of synthetic steps. This advancement addresses previous challenges in large-scale production and opens doors for more extensive structure-activity studies.

The pharmaceutical industry has shown growing interest in this scaffold, with several companies filing patents for (1R,4S)-2-azabicyclo[2.2.1]heptane-containing drug candidates in 2023-2024. These applications span diverse therapeutic areas including neurodegenerative diseases, psychiatric disorders, and inflammatory conditions. The compound's ability to cross the blood-brain barrier while maintaining metabolic stability makes it particularly valuable for CNS-targeted therapies.

Future research directions for (1R,4S)-2-azabicyclo[2.2.1]heptane derivatives include exploration of their potential in targeted protein degradation (PROTAC technology) and as molecular probes for studying biological systems. The scaffold's rigid structure and functionalization points make it an attractive candidate for these emerging technologies in chemical biology and drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)